{"id":47537,"date":"2026-05-26T11:39:02","date_gmt":"2026-05-26T09:39:02","guid":{"rendered":"https:\/\/hempika.com\/?page_id=47537"},"modified":"2026-05-29T08:57:15","modified_gmt":"2026-05-29T06:57:15","slug":"cbd-101","status":"publish","type":"page","link":"https:\/\/hempika.com\/en\/cbd-101\/","title":{"rendered":"CBD 101"},"content":{"rendered":"<div class=\"h-101\">\n<div class=\"h-101-top\">\n<h1>CBD 101<\/h1>\n<p><em>Everything you need to know about cannabidiol: from the science of how it works to choosing the right product, finding your dose, and understanding the research.<\/em><\/p>\n<p>  <img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/hempika.com\/wp-content\/themes\/hemp-master\/custom\/img\/hemp-plant.jpg\" alt=\"Hemp Plant\" width=\"100\" height=\"100\"><\/p><\/div>\n<div class=\"h-101-left\">\n<nav>\n<ol>\n<li><a href=\"#what-is-cbd\">What is CBD?<\/a><\/li>\n<li><a href=\"#how-cbd-works\">How CBD Works in the Body<\/a><\/li>\n<li><a href=\"#types-of-cbd-products\">Types of CBD Products<\/a><\/li>\n<li><a href=\"#full-spectrum-broad-spectrum-isolate\">Full-Spectrum, Broad-Spectrum and Isolate<\/a><\/li>\n<li><a href=\"#how-to-take-cbd\">How to Take CBD: Methods and Bioavailability<\/a><\/li>\n<li><a href=\"#cbd-dosage\">CBD Dosage: How to Find Your Dose<\/a><\/li>\n<li><a href=\"#what-research-says\">What the Research Says<\/a><\/li>\n<li><a href=\"#safety-and-side-effects\">CBD Safety and Side Effects<\/a><\/li>\n<li><a href=\"#drug-interactions\">CBD and Drug Interactions<\/a><\/li>\n<li><a href=\"#how-to-choose\">How to Choose a Quality CBD Product<\/a><\/li>\n<li><a href=\"#drug-tests\">CBD and Drug Tests<\/a><\/li>\n<li><a href=\"#legal-status\">Legal Status<\/a><\/li>\n<\/ol>\n<\/nav><\/div>\n<div class=\"h-101-right\">\n<section id=\"what-is-cbd\">\n<h2>1. What is CBD?<\/h2>\n<p>CBD, short for cannabidiol, is a naturally occurring compound found in the Cannabis sativa plant. It is the most abundant non-intoxicating cannabinoid in hemp and the most extensively studied. Unlike THC (tetrahydrocannabinol), CBD does not produce a &#8220;high&#8221; and is not associated with abuse or dependence potential.<\/p>\n<p>CBD was first isolated in 1940 and its complete structure identified in 1963 by Israeli chemist Raphael Mechoulam, who would go on to become one of the founding figures of cannabinoid science. For decades it remained a scientific curiosity. It was not until the discovery of the endocannabinoid system in the early 1990s that researchers began to understand why CBD and other cannabinoids have such wide-ranging effects in the human body.<\/p>\n<p>Today, CBD is one of the most discussed and commercially significant compounds in the global wellness industry. It is available in dozens of product formats, from oils and capsules to topical creams and food products, and the body of scientific research investigating its therapeutic potential grows every year.<\/p>\n<p>A few key facts worth establishing from the start:<\/p>\n<ul>\n<li>CBD is derived primarily from hemp, the low-THC variety of Cannabis sativa<\/li>\n<li>It is non-psychoactive: it will not get you high at any typical dose<\/li>\n<li>It is legal across the EU when derived from approved hemp varieties and compliant with Novel Food regulations<\/li>\n<li>It has one FDA-approved pharmaceutical application (the epilepsy drug Epidiolex) and a large body of ongoing clinical research<\/li>\n<li>It is not the same as hemp seed oil, which contains no meaningful cannabinoids<\/li>\n<\/ul>\n<\/section>\n<section id=\"how-cbd-works\">\n<h2>2. How CBD Works in the Body<\/h2>\n<p>CBD&#8217;s effects in the body are more complex and indirect than those of THC. Where THC binds directly and strongly to the CB1 receptors in the brain to produce intoxication, CBD does not work this way. Instead, it exerts its influence through multiple receptor targets and indirect mechanisms, which is one reason it has such a broad range of potential applications.<\/p>\n<h3>Indirect modulation of the endocannabinoid system<\/h3>\n<p>CBD inhibits the enzyme FAAH (fatty acid amide hydrolase), which is responsible for breaking down the body&#8217;s own endocannabinoid anandamide. By slowing this breakdown, CBD effectively raises anandamide levels in the system. Anandamide plays roles in mood regulation, pain signalling, and memory, which is why CBD&#8217;s influence on this pathway is of particular interest for anxiety and pain research.<\/p>\n<h3>TRPV1 receptor activation<\/h3>\n<p>CBD is a known agonist of TRPV1, the transient receptor potential vanilloid 1 channel, which is involved in pain signalling, inflammation, and body temperature regulation. This receptor is the same one activated by capsaicin (the compound that makes chillies hot), and its activation by CBD is one of the mechanisms proposed for CBD&#8217;s analgesic and anti-inflammatory properties.<\/p>\n<h3>Serotonin receptor activity<\/h3>\n<p>CBD activates the 5-HT1A serotonin receptor, which is one of the main targets of conventional antidepressant and anxiolytic medications. This interaction is thought to underlie at least part of CBD&#8217;s observed effects on anxiety and mood. The 5-HT1A receptor is involved in regulating emotional responses, sleep, and stress reactivity.<\/p>\n<h3>Negative allosteric modulation at CB1<\/h3>\n<p>Although CBD does not bind directly to CB1 receptors in the way THC does, it acts as a negative allosteric modulator at this receptor, meaning it changes the receptor&#8217;s shape in a way that reduces its response to other molecules including THC. This is why CBD can, in some contexts, counteract the psychoactive effects of THC, and why full-spectrum products containing both compounds behave differently from pure THC.<\/p>\n<h3>GPR55 and other receptor targets<\/h3>\n<p>CBD also interacts with GPR55 (a receptor sometimes called the &#8220;third cannabinoid receptor&#8221;), PPARgamma (a nuclear receptor relevant to metabolism and inflammation), and several other molecular targets. This multi-target pharmacology is unusual among single compounds and contributes to both CBD&#8217;s versatility and the complexity of studying it.<\/p>\n<h3>Why CBD does not get you high<\/h3>\n<p>The psychoactive effects of THC result from its direct, high-affinity binding to CB1 receptors in the brain, which disrupts normal neural signalling in areas governing perception, memory, and mood. CBD has very low binding affinity for CB1 receptors and does not trigger this effect. At typical consumer doses, CBD produces no intoxication, no impairment of coordination or memory, and no alteration of perception.<\/p>\n<\/section>\n<section id=\"types-of-cbd-products\">\n<h2>3. Types of CBD Products<\/h2>\n<p>CBD is now available in a wider range of formats than almost any other supplement. Each format has a different onset time, duration of effect, and bioavailability, which matters both for how you experience the effects and for how efficiently your body uses what you consume.<\/p>\n<h3>Oils and tinctures<\/h3>\n<p>CBD oil is the most widely used format and arguably the most versatile. It consists of a CBD extract dissolved in a carrier oil, typically MCT (medium-chain triglyceride) oil from coconut, hemp seed oil, or olive oil. Oils are taken sublingually (under the tongue) for faster absorption, or added to food and drink for slower, more gradual uptake. They allow flexible dosing and are available across a wide range of concentrations. Onset when taken sublingually is typically 15 to 45 minutes.<\/p>\n<h3>Capsules and softgels<\/h3>\n<p>CBD capsules contain a pre-measured dose of CBD extract in a digestible shell. They are convenient, discreet, and easy to incorporate into an existing supplement routine. Because they pass through the digestive system, onset is slower (typically 45 to 90 minutes) but the duration of effect tends to be longer than sublingual administration. Softgels with oil-based CBD tend to absorb more efficiently than dry powder capsules.<\/p>\n<h3>Topicals: creams, balms, and patches<\/h3>\n<p>Topical CBD products are applied directly to the skin and are designed to act locally rather than systemically. They do not deliver meaningful amounts of CBD into the bloodstream under normal use conditions, meaning they are not relevant for systemic effects on mood or sleep. Their primary application is localised discomfort or skin conditions. Transdermal patches differ from surface topicals: they are specifically engineered to drive CBD across the skin barrier and into systemic circulation over an extended period.<\/p>\n<h3>Edibles and food products<\/h3>\n<p>CBD gummies, chocolates, drinks, and other food products are popular for their convenience and palatability. Like capsules, they are processed through the digestive system, resulting in slower onset and lower bioavailability than sublingual formats. The absorption of CBD from edibles is significantly improved when taken alongside a fatty meal, as CBD is fat-soluble.<\/p>\n<h3>Vapes and inhalation<\/h3>\n<p>Inhaled CBD (via vaporiser or CBD flower) enters the bloodstream through the lungs, bypassing first-pass liver metabolism entirely. This gives inhalation the highest bioavailability of any CBD delivery route and the fastest onset, often within minutes. However, the respiratory risks associated with any form of inhalation are a genuine concern, and vaping products have faced regulatory scrutiny in several markets. Inhalation is not recommended for people with respiratory conditions.<\/p>\n<h3>Cosmetics<\/h3>\n<p>A growing range of skincare products include CBD as an ingredient, from serums and moisturisers to bath products. These are regulated as cosmetics rather than food supplements in most jurisdictions, and their primary purported benefits relate to skin-level anti-inflammatory and antioxidant effects. As with topicals, systemic CBD absorption from cosmetics is negligible.<\/p>\n<\/section>\n<section id=\"full-spectrum-broad-spectrum-isolate\">\n<h2>4. Full-Spectrum, Broad-Spectrum and Isolate<\/h2>\n<p>Beyond the delivery format, the type of CBD extract used in a product has a significant bearing on what you are actually consuming. There are three main categories.<\/p>\n<h3>Full-spectrum<\/h3>\n<p>Full-spectrum extracts contain the complete range of cannabinoids, terpenes, and other phytocompounds present in the hemp plant, including trace amounts of THC (within legal limits, typically below 0.2% in EU products). The advantage of full-spectrum is that it preserves the chemical complexity of the plant, allowing for potential synergistic interactions between compounds (the entourage effect). For most users, the trace THC content presents no psychoactive effect, but it is a consideration for people subject to drug testing or who are sensitive to THC.<\/p>\n<h3>Broad-spectrum<\/h3>\n<p>Broad-spectrum extracts retain the wider range of cannabinoids and terpenes found in full-spectrum, but undergo additional processing to remove THC to non-detectable levels. They are the practical choice for people who want the potential benefits of multiple plant compounds without any THC exposure. Quality varies significantly between brands, and it is worth checking the certificate of analysis to confirm that the broader cannabinoid profile is genuinely present.<\/p>\n<h3>CBD isolate<\/h3>\n<p>Isolate is purified CBD in its most concentrated form, typically 99% or more pure cannabidiol with no other plant compounds. It is flavourless and odourless, making it suitable for adding to other products or for people with sensitivities to terpenes or minor cannabinoids. It is also the most straightforward choice for people who want to know precisely how much CBD they are consuming or who need to be completely certain that no THC is present.<\/p>\n<table>\n<thead>\n<tr>\n<th><\/th>\n<th>Full-Spectrum<\/th>\n<th>Broad-Spectrum<\/th>\n<th>Isolate<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>CBD<\/strong><\/td>\n<td>Yes<\/td>\n<td>Yes<\/td>\n<td>Yes<\/td>\n<\/tr>\n<tr>\n<td><strong>Other cannabinoids<\/strong><\/td>\n<td>Yes<\/td>\n<td>Yes (THC removed)<\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td><strong>Terpenes<\/strong><\/td>\n<td>Yes<\/td>\n<td>Yes (usually)<\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td><strong>THC<\/strong><\/td>\n<td>Trace (up to 0.2%)<\/td>\n<td>Not detected<\/td>\n<td>None<\/td>\n<\/tr>\n<tr>\n<td><strong>Drug test risk<\/strong><\/td>\n<td>Low but possible<\/td>\n<td>Very low<\/td>\n<td>Minimal<\/td>\n<\/tr>\n<tr>\n<td><strong>Best for<\/strong><\/td>\n<td>Whole-plant benefit<\/td>\n<td>THC-sensitive users<\/td>\n<td>Precise dosing<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/section>\n<section id=\"how-to-take-cbd\">\n<h2>5. How to Take CBD: Methods and Bioavailability<\/h2>\n<p>Bioavailability refers to the proportion of a substance that actually enters your bloodstream and becomes available for the body to use. For CBD, bioavailability varies enormously depending on how you take it, and understanding this helps explain why the same milligram dose can feel very different across different product formats.<\/p>\n<h3>Sublingual (under the tongue)<\/h3>\n<p>Holding CBD oil under the tongue for 60 to 90 seconds allows absorption directly through the mucous membranes into the bloodstream, partially bypassing first-pass liver metabolism. This route provides faster onset than swallowing (typically 15 to 45 minutes) and higher bioavailability than oral ingestion alone. It is the most common method for CBD oils and tinctures, and one of the best balances of speed, efficiency, and ease of use.<\/p>\n<h3>Oral ingestion (swallowing)<\/h3>\n<p>When CBD is swallowed, it passes through the digestive system and the liver before entering circulation. The liver&#8217;s first-pass metabolism significantly reduces the amount of CBD that reaches the bloodstream. <a href=\"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full\/10.1111\/bcp.14617\" target=\"_blank\" rel=\"noopener\">Research published in the British Journal of Clinical Pharmacology<\/a> notes that oral bioavailability is approximately 5 to 13%, though this improves substantially when CBD is taken with a high-fat meal, as CBD is lipophilic (fat-soluble). Onset for swallowed CBD is typically 45 to 90 minutes, but effects may last longer than faster-acting routes.<\/p>\n<h3>Inhalation<\/h3>\n<p>Inhaled CBD bypasses first-pass metabolism entirely, entering the bloodstream directly through the lungs. This results in the highest bioavailability of any common delivery method and near-immediate onset. However, inhalation carries respiratory risks not present in other routes, and regulatory frameworks for CBD vaping products vary widely across Europe. It is not a recommended route for people with any respiratory condition.<\/p>\n<h3>Topical application<\/h3>\n<p>Surface topicals (creams, balms) act locally on skin and underlying tissues. They are not designed to deliver CBD into systemic circulation in meaningful quantities and should not be considered equivalent to oral or sublingual dosing for any application beyond skin-level effects. True transdermal delivery systems (patches using penetration enhancers) are different and can achieve systemic absorption.<\/p>\n<h3>Practical tips by route<\/h3>\n<ul>\n<li><strong>Sublingual oil:<\/strong> Hold under the tongue for at least 60 seconds before swallowing. Avoid eating or drinking for 15 minutes before and after.<\/li>\n<li><strong>Capsules and edibles:<\/strong> Take with a meal that includes healthy fats (avocado, olive oil, nuts) to significantly improve absorption.<\/li>\n<li><strong>Topicals:<\/strong> Apply to clean, dry skin and massage gently to encourage absorption. Use a generous amount for localised areas.<\/li>\n<\/ul>\n<\/section>\n<section id=\"cbd-dosage\">\n<h2>6. CBD Dosage: How to Find Your Dose<\/h2>\n<p>There is no universally established CBD dose for wellness use. The appropriate amount varies considerably from person to person depending on body weight, metabolism, the product type and its bioavailability, individual sensitivity, and the reason for use. This means the only reliable way to find the right dose for you is through gradual, self-guided titration.<\/p>\n<h3>The start low, go slow principle<\/h3>\n<p>The standard recommendation from most clinicians and researchers who work with CBD is to begin with a low dose and increase gradually over days or weeks until you find the amount that works for you. A common starting point for adults new to CBD is 10 to 20 mg per day. Some people find this sufficient; others require 50 mg or more. Clinical studies have used doses ranging from as low as 5 mg up to several hundred milligrams daily depending on the condition being studied.<\/p>\n<h3>Factors that influence your ideal dose<\/h3>\n<ul>\n<li><strong>Body weight and composition:<\/strong> Higher body weight generally correlates with a need for higher doses, though this is not a rigid rule.<\/li>\n<li><strong>Metabolism:<\/strong> Individual differences in how quickly your liver processes CBD affect both its intensity and duration of effect.<\/li>\n<li><strong>Product type:<\/strong> A 20 mg dose from a sublingual oil will deliver more CBD to your bloodstream than 20 mg from a capsule taken without food, due to bioavailability differences.<\/li>\n<li><strong>Reason for use:<\/strong> People using CBD for general daily wellness typically use lower doses than those using it for specific, acute concerns.<\/li>\n<li><strong>Tolerance:<\/strong> Some users report that effects become more consistent and predictable with regular use over several weeks.<\/li>\n<\/ul>\n<h3>A practical titration approach<\/h3>\n<p>Start with 10 to 15 mg once or twice daily for the first week. Assess how you feel after seven days. If you notice no effect, increase by 5 to 10 mg. Continue this process at weekly intervals until you find an effective amount or until you are comfortable with the dose. Keep a simple log of dose, time, and any observations; this makes the process far more informative.<\/p>\n<h3>Reading the label correctly<\/h3>\n<p>One of the most common sources of confusion is misreading CBD product labels. Always look for the total CBD content in milligrams (mg) for the whole bottle, and calculate the per-serving dose. A 10 ml bottle containing 500 mg CBD typically delivers around 5 mg per 0.1 ml drop, or roughly 16 mg per full pipette. Products labelled with a percentage (such as &#8220;5% CBD oil&#8221;) require a calculation: 5% of 10 ml (10,000 mg) is 500 mg total. When in doubt, check the certificate of analysis.<\/p>\n<p>If you are taking prescription medication, always consult a doctor before starting CBD. This is not a precaution to be skipped. See the drug interactions section below for why.<\/p>\n<\/section>\n<section id=\"what-research-says\">\n<h2>7. What the Research Says<\/h2>\n<p>The scientific literature on CBD has grown enormously over the past decade. It is important to read this evidence clearly: some areas have strong, well-controlled clinical trial data, while others remain at the level of preclinical research or small pilot studies. The distinction matters.<\/p>\n<h3>Strong clinical evidence: epilepsy<\/h3>\n<p>The most robust and well-established evidence for CBD in any medical context is in the treatment of specific epilepsy syndromes. <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1611618\" target=\"_blank\" rel=\"noopener\">A landmark 2017 Phase III clinical trial by Devinsky et al., published in the New England Journal of Medicine<\/a>, demonstrated that purified CBD (Epidiolex) significantly reduced seizure frequency in patients with Dravet syndrome compared to placebo. Subsequent trials confirmed similar efficacy in Lennox-Gastaut syndrome. On the basis of these trials, Epidiolex received FDA approval in 2018 and EMA approval in the EU. This represents the clearest, most rigorous evidence that a cannabinoid compound can function as a medicine.<\/p>\n<h3>Moderate and growing evidence: anxiety<\/h3>\n<p>Anxiety is one of the most commonly cited reasons people use CBD, and there is a meaningful body of research supporting this use, though most studies are still relatively small or use specific anxiety-provoking conditions rather than generalised anxiety disorder in daily life. <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6326553\/\" target=\"_blank\" rel=\"noopener\">A 2019 case series by Shannon et al. in The Permanente Journal<\/a>, following 103 adults using CBD as an adjunct to usual care, found that 79% reported decreased anxiety scores within the first month. The authors appropriately note the study&#8217;s open-label, non-randomised design and call for further controlled trials.<\/p>\n<p>Multiple smaller controlled studies have shown reductions in anxiety responses during tasks such as public speaking. Research into CBD&#8217;s mechanism (particularly its action at the 5-HT1A serotonin receptor) provides a plausible biological basis for these observations.<\/p>\n<h3>Moderate evidence: sleep<\/h3>\n<p>Sleep and anxiety are closely linked, and CBD&#8217;s effects on sleep are difficult to disentangle from its effects on anxiety. Most studies that have found CBD improves sleep have done so in populations where poor sleep was secondary to anxiety or pain. Evidence for CBD as a direct sleep aid in otherwise healthy individuals with no other sleep-disrupting condition is less well established. That said, CBD&#8217;s effects on GABA signalling, cortisol regulation, and the serotonin system offer plausible mechanisms for sleep-related benefits.<\/p>\n<h3>Growing evidence: pain and inflammation<\/h3>\n<p>The combination therapy Sativex (CBD and THC in a 1:1 ratio) has demonstrated efficacy for neuropathic pain and multiple sclerosis-related spasticity in controlled trials, and is approved for these indications in a number of European countries. For CBD alone, preclinical evidence for anti-inflammatory and analgesic effects is substantial. Human clinical trial data for isolated CBD in pain is growing but more mixed, and the FDA has not yet approved CBD for any pain indication. CBD&#8217;s TRPV1 agonism and its indirect elevation of anandamide offer credible mechanisms for pain modulation.<\/p>\n<h3>Early-stage research: neuroprotection<\/h3>\n<p>CBD has demonstrated neuroprotective effects in cell cultures and animal models relevant to Alzheimer&#8217;s disease, Parkinson&#8217;s disease, and traumatic brain injury. These findings are scientifically interesting but human clinical trials in these areas are at early stages. It would be premature to make any claims about CBD preventing or treating neurodegenerative conditions based on current evidence.<\/p>\n<h3>Early-stage research: addiction<\/h3>\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31109198\/\" target=\"_blank\" rel=\"noopener\">A 2019 randomised placebo-controlled trial by Hurd et al., published in The American Journal of Psychiatry<\/a>, found that CBD significantly reduced cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder, along with reductions in physiological stress markers. This is one of the most compelling early-stage findings in cannabinoid research, though it represents a single trial and further research is needed before any clinical application could be considered.<\/p>\n<h3>Early-stage research: skin conditions<\/h3>\n<p>Topical and oral CBD have shown anti-inflammatory activity relevant to acne and psoriasis in preclinical research, and several dermatology-oriented clinical trials are underway. The sebostatic (sebum-reducing) effect of CBD on human sebocytes observed in laboratory conditions has attracted particular attention for acne-prone skin.<\/p>\n<h3>Important context<\/h3>\n<p>Under EU regulations, food supplements containing CBD cannot carry medical claims. Nothing in this section constitutes medical advice or a claim that CBD treats, prevents, or cures any disease or condition. The research described is intended to provide an accurate picture of the current scientific landscape. Always consult a qualified healthcare professional for personal medical guidance.<\/p>\n<\/section>\n<section id=\"safety-and-side-effects\">\n<h2>8. CBD Safety and Side Effects<\/h2>\n<p><a href=\"https:\/\/cdn.who.int\/media\/docs\/default-source\/controlled-substances\/whocbdreportmay2018-2.pdf\" target=\"_blank\" rel=\"noopener\">The WHO&#8217;s 2018 Critical Review Report on CBD<\/a> concluded that it is generally well tolerated, exhibits no effects indicative of abuse or dependence potential, and presents no significant public health risk. This formal review by the world&#8217;s leading public health authority is the most comprehensive safety assessment of CBD to date and remains the foundation of regulatory decisions worldwide.<\/p>\n<h3>Known side effects<\/h3>\n<p>At doses used in consumer products (typically 10 to 75 mg per day), CBD is well tolerated by most people. The side effects most commonly reported in clinical trials, primarily at higher doses, include:<\/p>\n<ul>\n<li><strong>Dry mouth<\/strong> (the most common, related to CBD&#8217;s effects on salivary gland receptors)<\/li>\n<li><strong>Mild drowsiness or fatigue<\/strong> (more likely at higher doses or when combined with other sedating substances)<\/li>\n<li><strong>Changes in appetite<\/strong> (both increases and decreases reported)<\/li>\n<li><strong>Loose stools or digestive discomfort<\/strong> (particularly at high doses or with certain carrier oils)<\/li>\n<li><strong>Temporary changes in liver enzymes<\/strong> (observed at very high doses in clinical trials; relevant primarily at pharmaceutical-level doses)<\/li>\n<\/ul>\n<h3>Special populations<\/h3>\n<p><strong>Pregnancy and breastfeeding:<\/strong> There is insufficient safety data for CBD use during pregnancy or breastfeeding. Both the WHO and most regulatory bodies advise against use during these periods, and this guidance should be followed.<\/p>\n<p><strong>Children:<\/strong> Pharmaceutical CBD (Epidiolex) is administered to children under strict medical supervision for epilepsy. Over-the-counter CBD supplementation in children outside of medical supervision is not supported by sufficient safety evidence and is generally not recommended.<\/p>\n<p><strong>Elderly people:<\/strong> Older adults may metabolise CBD differently and may be more susceptible to side effects, particularly sedation and drug interactions. Lower starting doses are advisable, and consultation with a physician is recommended, especially given the higher likelihood of concurrent medication use.<\/p>\n<h3>CBD and alcohol<\/h3>\n<p>Combining CBD with alcohol may amplify the sedative effects of both substances. While moderate social use of alcohol alongside low-dose CBD is unlikely to cause serious harm for most people, high-dose CBD combined with significant alcohol intake is not advisable, and the interaction has not been extensively studied in humans.<\/p>\n<\/section>\n<section id=\"drug-interactions\">\n<h2>9. CBD and Drug Interactions<\/h2>\n<p>This is arguably the most practically important safety topic for anyone considering CBD who also takes prescription medication. CBD is metabolised by, and inhibits, a family of liver enzymes called the cytochrome P450 (CYP450) system. This system is responsible for processing a very large proportion of commonly prescribed drugs, meaning that CBD has the potential to alter how these drugs behave in the body.<\/p>\n<h3>How the interaction works<\/h3>\n<p>When CBD inhibits CYP450 enzymes (particularly CYP3A4, CYP2C9, and CYP2C19), it slows the breakdown of other drugs that depend on these same enzymes for metabolism. This means those drugs remain in the bloodstream at higher concentrations and for longer than intended. Depending on the drug, this can increase the risk of side effects or cause toxicity. In some cases, the opposite effect can occur if CBD induces (speeds up) an enzyme involved in a drug&#8217;s activation.<\/p>\n<p><a href=\"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.2973\" target=\"_blank\" rel=\"noopener\">A controlled clinical study by Bansal et al. (2023), published in Clinical Pharmacology and Therapeutics<\/a>, demonstrated that high-dose CBD significantly inhibited CYP2C19 and CYP2C9 activity in healthy participants, leading to substantially increased plasma concentrations of co-administered drugs. CYP2C19 activity was reduced by over 200% in the CBD condition compared to placebo.<\/p>\n<h3>Drug classes most commonly affected<\/h3>\n<ul>\n<li><strong>Blood thinners (anticoagulants):<\/strong> Warfarin is metabolised by CYP2C9. Several case reports have documented that CBD use increased warfarin&#8217;s anticoagulant effect, requiring dose reductions to maintain safe INR levels. This interaction is clinically significant and well documented.<\/li>\n<li><strong>Antiepileptics:<\/strong> CBD is known to increase levels of clobazam and its active metabolite, and this interaction was observed in Epidiolex trials. Other antiepileptic drugs sharing the same metabolic pathways may be similarly affected.<\/li>\n<li><strong>Immunosuppressants:<\/strong> Drugs like tacrolimus and ciclosporin are CYP3A4 substrates; CBD inhibition of this enzyme could raise their plasma levels.<\/li>\n<li><strong>Certain antidepressants and anxiolytics:<\/strong> Some SSRIs and benzodiazepines share metabolic pathways affected by CBD.<\/li>\n<li><strong>Statins and cardiovascular drugs:<\/strong> Several statins and some antiarrhythmics are CYP3A4 substrates.<\/li>\n<\/ul>\n<h3>The grapefruit analogy<\/h3>\n<p>A useful rule of thumb: if your medication comes with a warning to avoid grapefruit, it likely relies on the same CYP enzymes that CBD inhibits. Grapefruit contains furanocoumarins, which inhibit CYP3A4 in a similar (though not identical) way to CBD. If your prescription says &#8220;avoid grapefruit,&#8221; speak with your doctor before using CBD.<\/p>\n<h3>What to do<\/h3>\n<p>If you take any regular prescription medication, consult your doctor or pharmacist before starting CBD. This is particularly important for anticoagulants, antiepileptics, immunosuppressants, and any medication with a narrow therapeutic window. The interaction risk is real, predictable, and manageable with proper medical oversight. It is not a reason to avoid CBD categorically, but it is a reason not to start without professional guidance.<\/p>\n<\/section>\n<section id=\"how-to-choose\">\n<h2>10. How to Choose a Quality CBD Product<\/h2>\n<p>The CBD market is not uniformly regulated, and product quality varies considerably across brands. Knowing what to look for helps you avoid poor-quality products and ensures you are getting what you pay for.<\/p>\n<h3>Third-party lab testing and the Certificate of Analysis<\/h3>\n<p>The single most important indicator of a trustworthy CBD product is independent, third-party laboratory testing, with results published in a Certificate of Analysis (COA). A COA should confirm:<\/p>\n<ul>\n<li>The actual CBD content (in mg), which should closely match the label<\/li>\n<li>THC content, ideally below 0.2% and confirmed as compliant<\/li>\n<li>The cannabinoid profile (full-spectrum and broad-spectrum products should show CBG, CBN, and others)<\/li>\n<li>Absence of residual solvents from extraction<\/li>\n<li>Absence of heavy metals (lead, mercury, cadmium, arsenic)<\/li>\n<li>Absence of pesticides and mycotoxins<\/li>\n<li>Microbial safety (absence of harmful bacteria and moulds)<\/li>\n<\/ul>\n<p>The COA should be from an independent, accredited laboratory, not one owned by the brand. Reputable brands make their COAs easy to find, either on the product page or via a QR code on the packaging, and update them with each production batch.<\/p>\n<h3>Hemp source and cultivation<\/h3>\n<p>The quality of the hemp plant used in extraction has a direct bearing on the quality of the final product. Hemp is a bioaccumulator: it absorbs what is in the soil, including heavy metals and pesticides. Look for products made from hemp grown in the EU under certified organic or pesticide-free conditions, using approved cultivar varieties. EU-grown hemp is subject to agricultural oversight that is not present in all global markets.<\/p>\n<h3>Extraction method<\/h3>\n<p>Supercritical CO2 extraction is the industry benchmark for clean, high-quality CBD extraction. It uses pressurised carbon dioxide as a solvent, leaves no residual chemicals in the extract, and preserves the full cannabinoid and terpene profile effectively. Ethanol extraction is also widely used and can produce excellent results. Be cautious of products that do not disclose their extraction method, as cheaper hydrocarbon solvents (butane, propane) can leave harmful residues if not fully removed.<\/p>\n<h3>Label accuracy and transparency<\/h3>\n<p>A trustworthy product clearly states the total CBD content in milligrams on the label, lists all ingredients, identifies the extract type (full-spectrum, broad-spectrum, or isolate), and provides clear information about the recommended dose per serving. Vague labelling (percentage only, no mg, no extract type) is a red flag. Brands should also be clear about where their hemp is sourced and provide accessible customer support.<\/p>\n<h3>Price as a signal (but not the only one)<\/h3>\n<p>High-quality CBD production with proper testing is not cheap. Products priced dramatically below the market average are rarely economical: they typically reflect lower cannabinoid content than claimed, inferior hemp, poor extraction, or absent testing. That said, an expensive price tag is not a guarantee of quality. The COA is what matters; the price is a secondary indicator.<\/p>\n<\/section>\n<section id=\"drug-tests\">\n<h2>11. CBD and Drug Tests<\/h2>\n<p>Standard workplace drug tests (immunoassay urine tests) do not screen for CBD itself. They screen for THC metabolites, specifically THC-COOH (11-nor-9-carboxy-THC), which is the compound your liver produces when processing THC. A positive result is triggered when THC-COOH exceeds a defined threshold concentration in urine.<\/p>\n<h3>Can CBD products trigger a positive drug test?<\/h3>\n<p>For most people using broad-spectrum or isolate CBD products, the risk is very low. However, full-spectrum products do contain trace amounts of THC, and with regular use at higher doses, there is a genuine (if small) possibility of accumulating THC-COOH above the detection threshold. Individual factors including body fat (THC metabolites are stored in fat tissue), frequency of use, dose, and product quality all affect this risk.<\/p>\n<p>Cross-contamination during manufacturing is another consideration. Some isolate or broad-spectrum products from less rigorous manufacturers have been found to contain detectable THC that was not disclosed on the label. This is precisely why COA verification matters: look specifically for THC listed as &#8220;not detected&#8221; (ND) or below the laboratory&#8217;s limit of quantification (LOQ).<\/p>\n<h3>Practical guidance for people subject to testing<\/h3>\n<ul>\n<li>Choose a broad-spectrum or isolate product with a recent, batch-specific COA confirming non-detectable THC<\/li>\n<li>If you are subject to regular or random testing in a professional context, inform your occupational health provider that you use CBD<\/li>\n<li>Be aware that &#8220;CBD only&#8221; or &#8220;0% THC&#8221; claims on labels without supporting COA evidence cannot be taken at face value<\/li>\n<li>CBD in any form does not protect against a positive test if you have separately used THC-containing cannabis<\/li>\n<\/ul>\n<\/section>\n<section id=\"legal-status\">\n<h2>12. Legal Status<\/h2>\n<p>The legal framework for CBD is more nuanced than media coverage often suggests, and it varies significantly between jurisdictions.<\/p>\n<h3>European Union<\/h3>\n<p>In the EU, CBD derived from approved hemp varieties (containing less than 0.3% THC at the plant level) is legal to sell as a food supplement. However, following a 2019 decision by the European Commission, CBD extracts used in food and food supplements are classified as <strong>Novel Foods<\/strong> under EU Regulation 2015\/2283. This means that companies placing CBD food products on the EU market must submit a Novel Food authorisation application to the European Food Safety Authority (EFSA). Many applications are in progress; the regulatory landscape continues to develop.<\/p>\n<p>Maximum THC limits in finished products vary by member state: 0.2% is the most common threshold in Western Europe, but some countries (including France and others) apply stricter limits. Always check the specific rules in your country.<\/p>\n<h3>United Kingdom<\/h3>\n<p>The UK&#8217;s Food Standards Agency (FSA) regulates CBD food supplements as Novel Foods post-Brexit. Companies must appear on the FSA&#8217;s validated list to legally market CBD food products. THC is a Class B controlled substance in the UK; finished CBD products must contain no more than 1 mg of THC per container, regardless of the container&#8217;s total volume or weight.<\/p>\n<h3>United States<\/h3>\n<p>The 2018 Farm Bill legalised hemp (defined as Cannabis sativa with less than 0.3% THC) at the federal level and removed hemp-derived CBD from the Controlled Substances Act. However, the FDA does not permit CBD to be added to food or marketed as a dietary supplement under current rules, as CBD was first approved as a drug (Epidiolex) before any food supplement application was submitted. This regulatory gap has created an unusual situation where CBD products are widely sold but operate in legal ambiguity at the federal level. State-level rules vary considerably.<\/p>\n<h3>A note on hemp-derived vs synthetic cannabinoids<\/h3>\n<p>Legal CBD products contain cannabidiol derived from the hemp plant. Synthetic CBD analogues and other synthetic cannabinoids (including delta-8-THC and HHC, which are often produced by chemically converting hemp-derived CBD) exist in varying legal grey areas across Europe and should not be confused with standard hemp-derived CBD.<\/p>\n<\/section><\/div>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CBD 101 Everything you need to know about cannabidiol: from the science of how it works to choosing the right product, finding your dose, and understanding the research. What is CBD? How CBD Works in the Body Types of CBD Products Full-Spectrum, Broad-Spectrum and Isolate How to Take CBD: Methods and Bioavailability CBD Dosage: How [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"custom-page-template.php","meta":{"footnotes":""},"class_list":["post-47537","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/hempika.com\/en\/wp-json\/wp\/v2\/pages\/47537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hempika.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/hempika.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/hempika.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hempika.com\/en\/wp-json\/wp\/v2\/comments?post=47537"}],"version-history":[{"count":0,"href":"https:\/\/hempika.com\/en\/wp-json\/wp\/v2\/pages\/47537\/revisions"}],"wp:attachment":[{"href":"https:\/\/hempika.com\/en\/wp-json\/wp\/v2\/media?parent=47537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}